Low gradient and LV Dysfunction: TAVI or not?

Original Title: Impact of ejection fraction and aortic valve gradient on outcomes of transcatheter aortic valve replacement.

Reference: Baron SJ et al. J Am Coll Cardiol. 2016;67:2349-2358.

 

Stethoscope with heart on suit background, close-up

Low aortic valve gradient and left ventricular dysfunction are frequent in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVI) but only low aortic valve gradient is associated with worse prognosis at one year, according to the recently published Transcatheter Valve Therapy (TVT) registry.

These findings suggest that low aortic valve gradient in patients with aortic stenosis is an important factor to consider when assessing risk/benefit ratio, since it has an important impact prognosis compared to low ejection fraction, which doesn’t seem as important.

Aside from this, neither of these two factors, separately or combined, seems to be enough not to prescribe TAVI.

Patients with severe LV dysfunction and low aortic valve gradient have 33% 1 year mortality, as observed in patients with this characteristics submitted to medical treatment in the PARTNER B.

This trial assessed data from 11292 patients undergoing TAVI between 2011 and 2014 included in the TVT registry (Society of Thoracic Surgeons/American College of Cardiology).

Patients were divided in three groups according to ventricular dysfunction:

  • Severe dysfunction (<30%).
  • Mild to moderate dysfunction (30-50%).
  • Preserved (>50%).

Aortic valve gradient was considered low (<40 mmHg) or high (≥40 mmHg). Mean gradient was lower in patient with severe LV dysfunction. LV function was worse in patients with low gradient.

Outcomes:

  • Patents with LV dysfunction and low aortic valve gradient had more prolonged post procedure hospitalization and had higher in hospital mortality. AT one year follow up, both factors were associated with higher risk of death and heart failure.
  • Patients with preserved LV dysfunction and high gradient had better prognosis at one year (23.6% mortality and 11.2% heart failure) compared to those with LV dysfunction and low gradient, with much worse prognosis (33.1% y 23.6%, respectively).
  • In multivariable analyzis, only low gradient was associated to higher mortality (HR 1.21; CI 95% 1.11-1.32) and recurrent heart failure (HR 1.52; CI 95% 1.36-1.69). These events and LV dysfunction were not significantly associated.

Editorial Comment

The greatest strength of this study was the big number of real world patients, and the limitation, that there was no “core lab” to adjudicate events, echocardiographic data was limited and of course there was no control group.

The information on aortic valve gradient, valve area, flow and ejection fraction, should be systematically integrated when stratifying severe aortic stenosis patients.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...